Regeneron Pharmaceuticals management check

REGN · Health Care · Biotechnology · CEO Leonard S. Schleifer

Filings as of

77
Management score, ranked 88th of 487 · 8th of 60 in Health Care4 good · 2 to watch · 1 flaggedStrongest: CEO cost · Weakest: owner returns · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$160Peers$201

    What $100 became since fiscal 2021

    2432nd
    Detail

    $100 invested at the start of fiscal 2021 grew to $160, against $201 for the peer group the company picked itself.

  • Watch

    Does pay follow performance?

    Pay only loosely tracked returns20212025

    Pay actually paid $100 value, each on its own scale

    6019th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.20 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.2% of net income

    $7.3m pay · $4.5bn net income, FY2025

    0.1%1%3%10%
    100100th
    Detail

    $7.3m of reported pay in fiscal 2025, against $4.5bn of net income.

  • Watch

    Do they own the stock?

    Insiders are selling

    6 mo: ▲ $0 bought · ▼ $60.3m sold

    ——
    Detail

    10 insiders sold $60.3m in the last six months and none bought. 65 of 96 sales ran on pre-arranged 10b5-1 plans.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 112m2025 · 109m

    Diluted shares −2.3% a year; flagged above +2%

    0%10%20%

    Stock pay 6.9% of revenue

    7871st
    Detail

    Diluted shares changed -2.3% a year over the last three fiscal years. Stock-based pay was 6.9% of revenue in the latest year.

  • Good

    Is leadership stable?

    2 leadership filings in 3 years

    2 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Leonard S. Schleifer

    100100th
    Detail

    CEO in the pay table: Leonard S. Schleifer. 2 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed April 24, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
−$37.7m$51.7m$141.1m$10020212022202320242025$160$201

Pay tied most to stock price

Other key measuresStock PriceRegulatory submissions for new products or indicationsTSRPositive data readoutsNon-GAAP diluted EPSNew Investigational New Drug ApplicationsApprovals of new products or indications

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Leonard S. Schleifer$7.3m$39.0m$7.7m$160$201$4.5bn
2024Leonard S. Schleifer$6.8m−$37.7m$6.1m$147$156$4.4bn
2023Leonard S. Schleifer$8.2m$141.1m$6.7m$182$144$4.0bn
2022Leonard S. Schleifer$7.0m$98.8m$8.1m$149$139$4.3bn
2021Leonard S. Schleifer$6.5m$123.7m$7.5m$131$124$8.1bn

Insiders and the CEO's stakeSelling

10 insiders sold $60.3m in the last six months and none bought. 65 of 96 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldGeorge L SingDirector$22.3mNov 17, 2026
  • SoldAndrew J MurphyCo-Chief Scientific Officer · 10b5-1 plan$8.0mNov 17, 2026
  • SoldHuda Y ZoghbiDirector$7.9mNov 3, 2026
  • SoldChristine A PoonDirector$7.6mNov 2, 2026

Leadership and governance on file

20222023202420252026Leadership 5Votes 6
All 5 filings

Latest shareholder vote results: Jun 17, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $12.4bn returned to owners in buybacks and dividends, 49% of net income, and $4.2bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$4.0bn$8.1bn20212022202320242025Shares112m114m114m115m109m
Show the figures
Fiscal year20212022202320242025
Revenue$16.1bn$12.2bn$13.1bn$14.2bn$14.3bn
Net income$8.1bn$4.3bn$4.0bn$4.4bn$4.5bn
Stock-based pay$601.7m$725.0m$885.0m$982.8m$993.7m
Buybacks$1.6bn$2.1bn$2.2bn$2.6bn$3.4bn
Dividends——$0$0$370.3m
Diluted shares112m114m114m115m109m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.